Insider Selling: Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells 23,463 Shares of Stock

Key Points

• CEO Fred Aslan sold 23,463 Artiva Biotherapeutics shares at an average price of $7.20, generating $168,933.60. He now directly owns 1,519,606 shares, a 1.52% reduction in his position, following additional sales in October and September.
• Artiva shares fell to $7.00, well below their 50-day moving average of $10.02 and 200-day average of $9.23. The stock has a market capitalization of approximately $342 million and a 52-week range of $2.71 to $14.53.
• Analyst sentiment remains broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $39.00, despite the company’s expected full-year loss and clinical-stage status.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) CEO Fred Aslan sold 23,463 shares of the business's stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $7.20, for a total transaction of $168,933.60. Following the completion of the transaction, the chief executive officer directly owned 1,519,606 shares of the company's stock, valued at approximately $10,941,163.20. This represents a 1.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Fred Aslan also recently made the following trade(s):

• On Monday, October 5th, Fred Aslan sold 61,696 shares of Artiva Biotherapeutics stock. The shares were sold at an average price of $6.84, for a total value of $422,000.64.
• On Tuesday, September 8th, Fred Aslan sold 23,429 shares of Artiva Biotherapeutics stock. The shares were sold at an average price of $10.92, for a total value of $255,844.68.

Artiva Biotherapeutics Stock Performance

Artiva Biotherapeutics stock traded down $0.27 during trading on Wednesday, hitting $7.00. The company's stock had a trading volume of 324,471 shares, compared to its average volume of 393,273. The stock's fifty day moving average is $10.02 and its 200 day moving average is $9.23. Artiva Biotherapeutics, Inc. has a 1-year low of $2.71 and a 1-year high of $14.53. The stock has a market capitalization of $342.23 million, a price-to-earnings ratio of -2.12 and a beta of 2.40.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, meeting the consensus estimate of ($0.63). On average, research analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.62 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ARTV has been the topic of a number of research analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $40.00 price target on shares of Artiva Biotherapeutics in a report on Friday, October 2nd. HC Wainwright reaffirmed a "buy" rating on shares of Artiva Biotherapeutics in a research report on Friday, October 2nd. Wall Street Zen upgraded Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $39.00.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ARTV. BlackRock Inc. purchased a new position in Artiva Biotherapeutics in the second quarter valued at about $6,739,000. ADAR1 Capital Management LLC purchased a new stake in shares of Artiva Biotherapeutics in the second quarter worth about $1,151,000. Nantahala Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the second quarter valued at about $2,910,000. Alyeska Investment Group L.P. grew its stake in shares of Artiva Biotherapeutics by 173.6% in the second quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company's stock valued at $2,654,000 after buying an additional 173,615 shares in the last quarter. Finally, Blue Owl Capital Holdings LP purchased a new stake in shares of Artiva Biotherapeutics during the 2nd quarter valued at about $8,483,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc NASDAQ: ARTV is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company's approach is designed to produce off-the-shelf cell therapies that can be manufactured at scale and administered without using cells collected from each individual patient.

Artiva's lead investigational product, AlloNK, also known as AB-101, is an allogeneic NK cell therapy being evaluated in combination with rituximab for autoimmune conditions, including systemic lupus erythematosus and lupus nephritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.